2024
Health‐Related Quality of Life in Women With Metastatic Breast Cancer: An Integrative Review
Zhan Y, Feder S, Lustberg M, Batten J, Knobf M. Health‐Related Quality of Life in Women With Metastatic Breast Cancer: An Integrative Review. Journal Of Advanced Nursing 2024 PMID: 39584570, DOI: 10.1111/jan.16643.Peer-Reviewed Original ResearchHealth-related quality of lifeHealth-related qualityQuality of lifeIntegrative reviewJoanna Briggs Institute appraisal checklistAssess health-related quality of lifeImprove health-related quality of lifeNon-Hispanic white womenImprove health-related qualityBreast cancer experienceFull-text papersBreast cancerProtective factorsCancer experienceIndividualised careSymptom experienceSymptom managementWeb of ScienceAppraisal checklistRacially diverse samplePhysical symptomsReview guidelinesPsychological symptomsMetastatic breast cancerWhite womenOutcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageThe Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatmentFeasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
Buga A, Harper D, Sapper T, Hyde P, Fell B, Dickerson R, Stoner J, Kackley M, Crabtree C, Decker D, Robinson B, Krystal G, Binzel K, Lustberg M, Volek J. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLOS ONE 2024, 19: e0296523. PMID: 38166036, PMCID: PMC10760925, DOI: 10.1371/journal.pone.0296523.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerStage IV metastatic breast cancerKetogenic dietInsulin resistanceNutritional ketosisPlasma insulinBreast cancerBody compositionAdjuvant therapeutic interventionsMetabolic outcomesCancer patientsPlasma glucoseMetabolic effectsBody fatShort-term studiesBody weightPleiotropic mechanismsTherapeutic interventionsConsistent bloodPhase IMonthsWomenCancerAd libitumChemotherapy
2023
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.Peer-Reviewed Original ResearchMetastatic breast cancerLobular histologyBreast cancerHER2 IHCGenomic alterationsComprehensive genomic profiling studyPD-L1 gene amplificationImmune checkpoint inhibitor treatmentMicrosatellite instabilityAxillary LN metastasisMetastatic site biopsySubset of ptsStage IV diseaseCheckpoint inhibitor treatmentPD-L1 expressionTumor mutational burdenMutations/MbMSI-high statusHER2 IHC resultsGenomic profiling studiesSite biopsiesSP142 assayLN metastasisMetastatic diseaseHigh TMBRetrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Minta A, Rose L, Park C, Trovato S, Lustberg M, Sudheendra P, Cherian M, Gatti-Mays M, Stover D, Wesolowski R, Sardesai S, Ramaswamy B, Williams N, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal Of Clinical Oncology 2023, 41: e13083-e13083. DOI: 10.1200/jco.2023.41.16_suppl.e13083.Peer-Reviewed Original ResearchBreast cancerEIA patientsDermatology referralsOnset of alopeciaRetrospective cohort studyMetastatic breast cancerRisk of alopeciaCyclin-dependent kinase 4Endocrine monotherapyOral minoxidilEndocrine therapyClinical improvementCohort studyRetrospective cohortFemale patientsTherapeutic optionsCombination therapyGrade severityTherapeutic responseFavorable outcomeAndrogenetic alopeciaDean scaleCDK4/6iPatientsSignificant improvementIdentifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach.
Radwan R, Hertz D, Hickey E, Vachhani H, Lustberg M, Bridges J, Sabo R, Sheppard V, Salgado T. Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach. Journal Of Clinical Oncology 2023, 41: e13123-e13123. DOI: 10.1200/jco.2023.41.16_suppl.e13123.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyMetastatic breast cancerPeripheral neuropathyTreatment alterationsTreatment effectivenessMBC patientsCIPN symptomsMedical oncologistsDiscontinue treatmentClinical guidelinesOncology cliniciansCommunity-centered approachEffective therapyBreast cancerChemotherapy agentsTreatment decisionsPatient prioritiesPatient's perspectiveDose reductionAlternative treatmentOptimize outcomesPatientsSide effectsTreatment planHealthcare providers
2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapyThe mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategiesTreatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factorCLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
Quiroga D, Pinette A, Benner B, Schwarz E, Wesolowski R, Stiff A, Zelinskas S, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2022, 20: clo22-079. DOI: 10.6004/jnccn.2021.7196.Peer-Reviewed Original ResearchPhase II open-label studyOpen-label studyMetastatic breast cancerCpG ODNBreast cancerPatientsTrastuzumabCancer
2021
Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations.
Collier K, Tallman D, Weber Z, Haynam M, Adams E, Jenison J, Asad S, Lustberg M, Cherian M, Ramaswamy B, Sardesai S, Williams N, Wesolowski R, VanDeusen J, Gatti-Mays M, Pariser A, Mortazavi A, Stover D. Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations. Journal Of Clinical Oncology 2021, 39: 1025-1025. DOI: 10.1200/jco.2021.39.15_suppl.1025.Peer-Reviewed Original ResearchMetastatic breast cancerTargeted panel sequencingPlatinum chemotherapySomatic copy number alterationsPARP inhibitorsBreast cancerPlasma samplesSerial ctDNA samplesHormone receptor statusNon-invasive evaluationPass whole genome sequencingDNA damage repair genesLast time pointTumor DNA samplesReceptor statusHR statusControl cohortLast timepointBRCA1/2 mutationsSomatic BRCA1Blood samplesCancer-related genesCtDNA samplesSerial samplesTumor fractionSurvival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.
Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.Peer-Reviewed Original ResearchFirst-line endocrine therapyProgression-free survivalInvasive lobular carcinomaMedian progression-free survivalEndocrine therapyMedian overall survivalOverall survivalBreast cancerDuctal cancerLobular cancerEstrogen receptor/progesterone receptorMetastatic invasive lobular carcinomaOhio State University Comprehensive Cancer CenterDistinct clinicopathologic characteristicsInitial endocrine therapyInitiation of chemotherapyYear of diagnosisKaplan-Meier methodMetastatic breast cancerSite of metastasisInvasive breast cancerSingle-institution studyComprehensive cancer centerLine endocrine therapyConcerns of resistance
2020
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).
Okines A, Paplomata E, Wahl T, Wright G, Sutherland S, Jakobsen E, Valdes F, Chan A, Clark A, Conlin A, Lustberg M, Specht J, Pluard T, Zhu X, Krop I, Gelmon K, Slamon D, Ramos J, An G, Hamilton E. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). Journal Of Clinical Oncology 2020, 38: 1043-1043. DOI: 10.1200/jco.2020.38.15_suppl.1043.Peer-Reviewed Original ResearchAdverse eventsMedian timeControl armBreast cancerExposure-adjusted incidence ratesElevated liver enzymesMetastatic breast cancerCases of diarrheaMedian durationDose modificationTx groupIncidence rateLiver enzymesHigh incidenceDiarrheaTucatinibFirst onsetCapecitabineTrastuzumabHER2Significant inhibitionBilirubinLonger durationCycle 1Patients
2014
Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin
Pahouja G, Wesolowski R, Reinbolt R, Tozbikian G, Berger M, Mangini N, Lustberg M. Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. Cancer Treatment And Research Communications 2014, 3: 28-32. PMID: 25914871, PMCID: PMC4408922, DOI: 10.1016/j.ctrc.2014.11.002.Peer-Reviewed Original ResearchBone marrow infiltrationMetastatic breast cancerBreast cancerPatient's thrombocytopeniaMarrow infiltrationPlatelet transfusionsProfound pancytopeniaDramatic responseAppropriate systemic treatmentBaseline platelet levelDaily platelet transfusionsFull platelet recoveryBone marrow metastasesFrequent platelet transfusionsSimilar patient experiencesBone marrow failureCatastrophic bleedingMetastatic diseaseSystemic treatmentMarrow metastasesTumor involvementPlatelet levelsPlatelet recoveryPatient experienceBone marrowCSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
Mathsyaraja H, Thies K, Taffany D, Deighan C, Liu T, Yu L, Fernandez S, Shapiro C, Otero J, Timmers C, Lustberg M, Chalmers J, Leone G, Ostrowski M. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene 2014, 34: 3651-3661. PMID: 25241894, PMCID: PMC4369473, DOI: 10.1038/onc.2014.294.Peer-Reviewed Original ResearchConceptsTumor-infiltrating myeloid cellsMetastatic tumor growthMyeloid cellsMiR-21Breast cancerTumor growthHuman metastatic breast cancerMetastatic tumor burdenMetastatic breast cancerPro-tumor functionsAnti-angiogenic genesAttractive therapeutic targetTumor cell proliferationPro-angiogenic propertiesMature myeloid cellsTumor burdenMonocytes correlatesPoor prognosisMelanoma metastasesMouse modelTherapeutic targetSolid tumorsOncogenic roleSurvival rateTherapeutic efficacyPhase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).
Wesolowski R, Zhao M, Geyer S, Lustberg M, Mrozek E, Layman R, Macrae E, Zhang J, Hall N, Schregel K, Ottman S, Camp A, Chalmers J, Andreopoulou E, Villalona-Calero M, Shapiro C, Knopp M, Grever M, Ramaswamy B. Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC). Journal Of Clinical Oncology 2014, 32: 1074-1074. DOI: 10.1200/jco.2014.32.15_suppl.1074.Peer-Reviewed Original ResearchHeterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
Lustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae E, Wesolowski R, Layman R, Mrozek E, Pan X, Summers T, Shapiro C, Chalmers J. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research 2014, 16: r23. PMID: 24602188, PMCID: PMC4053256, DOI: 10.1186/bcr3622.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesCell Line, TumorEpithelial Cell Adhesion MoleculeErbB ReceptorsFemaleFlow CytometryHumansImmunohistochemistryKeratin-18Keratin-19Keratin-8Leukocyte Common AntigensMCF-7 CellsMicroscopy, ConfocalMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisProspective StudiesVimentinConceptsMetastatic breast cancerBreast cancer patientsBlood samplesCancer patientsBreast cancerMetastatic breast cancer patientsPatient samplesMultiparametric flow cytometry analysisAtypical cell populationNumber of CKPresent prospective trialWorse overall survivalTumor-associated macrophagesCell populationsPan-hematopoietic marker CD45Confocal microscopyEpidermal growth factor receptorEpithelial cell adhesion moleculeNormal control samplesCell surface markersRole of EpCAMFlow cytometry analysisGrowth factor receptorOverall survivalProspective trial
2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
Lustberg M, Pant S, Ruppert A, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen R, Berger M, Mrozek E, Ramaswamy B, Grever M, Au J, Wientjes M, Shapiro C. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy And Pharmacology 2012, 70: 49-56. PMID: 22729159, PMCID: PMC3466596, DOI: 10.1007/s00280-012-1887-x.Peer-Reviewed Original ResearchConceptsObjective response rateMetastatic breast cancerWeekly paclitaxelAnti-tumor activityII trialBreast cancerPhase I/II trialMedian progression-free survivalGrowth factorPhase IMedian overall survivalResultsThirty-one patientsPhase II trialProgression-free survivalDose-limiting toxicityBasic fibroblast growth factorPre-specified criteriaNon-cytotoxic dosesFibroblast growth factorPrior taxaneMetastatic settingUnacceptable toxicityOverall survivalPolypeptide growth factorsSuramin concentrations